Middle East Regulatory Policy Brief

[Middle East] Key Regulatory Updates: Semaglutide, Sanctions & Healthcare Licensing

Middle East Regulatory Policy Brief

Show Notes

Covering Semaglutide, Sheryan, Sanctions, Bank Melli Iran, Healthcare Licensing. This episode covers critical regulatory developments on semaglutide safety updates, UAE sanctions on Bank Melli Iran, Dubai’s new Sheryan healthcare licensing system, mandatory medical internships, and Saudi Arabia’s veterinary product reporting service.

More from Middle East Regulatory Policy Brief

Oct 12, 2026

Covering Consultation Paper, Warehouse, Digital Platform, Energy Security, Spectrum Fee. Explore major regulatory developments including enhanced strata consultation papers, new digital licensing for pharmaceutical warehouses, and ongoing spectrum fee consultations. Updates impact sectors like Consultation Paper, Warehouse, Digital Platform, Energy Security, and Spectrum Fee.

Oct 5, 2026

Covering Regulatory Compliance, OFAC, Telecommunication, Service Delivery, Sanctions. Explore critical updates in Regulatory Compliance, OFAC sanctions, Telecommunication digital policies, Service Delivery enhancements, and Sanctions enforcement across the Middle East.

Sep 21, 2026

Covering Pharmacovigilance, Labelling, Packaging Defect, Ministerio para la Transición Ecológica y el Reto Demográfico, State Water Resources Control Board. Key regulatory updates covering Pharmacovigilance, Labelling, and Packaging Defect in Saudi Arabia, alongside insights on Ministerio para la Transición Ecológica y el Reto Demográfico and State Water Resources Control Board sectors.

Sep 14, 2026

Covering GCC, Sanctions, Procurement, SFDA, Operational Workflows. Explore key regulatory developments across GCC sectors including SFDA enforcement actions, AI medical software approvals, capital market reforms, sanctions on Iran, and operational workflow enhancements at Jeddah Port.

Sep 7, 2026

Covering Patient Safety, Drug Safety, Pharmacovigilance, Osteonecrosis of the Jaw, Pharmaceutical. This episode covers critical regulatory developments in patient safety, pharmacovigilance, and pharmaceutical oversight, including updated educational materials for Atrasentan, Denosumab, and Adalimumab, plus voluntary recalls impacting multiple drug batches.

See all episodes →